UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Cuts Holdings in DENTSPLY SIRONA Inc. $XRAY

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC decreased its holdings in DENTSPLY SIRONA Inc. (NASDAQ:XRAY) by 28.8% in the second quarter, HoldingsChannel.com reports. The institutional investor owned 452,599 shares of the medical instruments supplier’s stock after selling 182,661 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in DENTSPLY SIRONA were worth $4,802,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Hsbc Holdings PLC increased its holdings in shares of DENTSPLY SIRONA by 225.7% in the 2nd quarter. Hsbc Holdings PLC now owns 43,973 shares of the medical instruments supplier’s stock valued at $464,000 after acquiring an additional 30,470 shares during the period. Kingsview Wealth Management LLC purchased a new stake in shares of DENTSPLY SIRONA during the 2nd quarter worth $205,000. Empowered Funds LLC purchased a new stake in shares of DENTSPLY SIRONA during the second quarter valued at about $421,000. Public Employees Retirement System of Ohio purchased a new stake in shares of DENTSPLY SIRONA during the second quarter valued at about $69,000. Finally, Capstone Investment Advisors LLC bought a new stake in shares of DENTSPLY SIRONA in the 2nd quarter valued at about $458,000. Hedge funds and other institutional investors own 95.70% of the company’s stock.

Insiders Place Their Bets

In related news, Director Brian McKeon acquired 10,000 shares of the company’s stock in a transaction dated Friday, June 12th. The shares were purchased at an average cost of $10.12 per share, with a total value of $101,200.00. Following the completion of the acquisition, the director directly owned 10,000 shares of the company’s stock, valued at $101,200. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Brian Gladden bought 9,985 shares of the business’s stock in a transaction that occurred on Monday, June 15th. The stock was purchased at an average cost of $10.02 per share, for a total transaction of $100,049.70. Following the completion of the transaction, the director owned 61,849 shares in the company, valued at $619,726.98. This trade represents a 19.25% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. 0.46% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several research firms recently commented on XRAY. BMO Capital Markets reiterated a “market perform” rating and set a $13.00 price objective on shares of DENTSPLY SIRONA in a research note on Friday, August 7th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of DENTSPLY SIRONA in a report on Monday, August 3rd. Piper Sandler upped their price target on DENTSPLY SIRONA from $13.00 to $14.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 29th. Barclays increased their price objective on DENTSPLY SIRONA from $9.00 to $11.00 and gave the company an “underweight” rating in a report on Monday, August 24th. Finally, Barrington Research set a $15.00 price objective on DENTSPLY SIRONA in a research report on Monday, August 10th. Three investment analysts have rated the stock with a Buy rating, nine have given a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $13.54.

DENTSPLY SIRONA Stock Performance

Shares of DENTSPLY SIRONA stock opened at $10.72 on Thursday. The company has a 50 day moving average price of $12.18 and a 200 day moving average price of $11.63. The firm has a market capitalization of $2.14 billion, a P/E ratio of -3.90, a PEG ratio of 1.40 and a beta of 0.84. The company has a quick ratio of 1.07, a current ratio of 1.63 and a debt-to-equity ratio of 1.48. DENTSPLY SIRONA Inc. has a 52 week low of $9.40 and a 52 week high of $14.76.

DENTSPLY SIRONA (NASDAQ:XRAY) last released its earnings results on Thursday, August 6th. The medical instruments supplier reported $0.52 earnings per share for the quarter, topping the consensus estimate of $0.35 by $0.17. DENTSPLY SIRONA had a negative net margin of 14.99% and a positive return on equity of 20.84%. The company had revenue of $898.00 million for the quarter, compared to the consensus estimate of $889.93 million. During the same quarter in the previous year, the firm earned $0.52 EPS. DENTSPLY SIRONA’s revenue was down 4.1% compared to the same quarter last year. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. Sell-side analysts expect that DENTSPLY SIRONA Inc. will post 1.4 EPS for the current year.

DENTSPLY SIRONA Company Profile

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.